Alexza Pharmaceuticals Inc fka ALXA

[operating_line]

DOWN BUT NOT OUT: Solid Press Release
http://www.prnewswire.com/news-releases/ferrer-and-alexza-pharmaceuticals-provide-update-on-adasuve-european-and-latin-american-commercial-activities-300159392.html

It has been a very bumpy road so far but there is sustained and clear product acceptance by end users, an increasing foothold in the medical community (peer reviewed publications) followed by ongoing market expansion expansion.

Key points:
"In the past year, there have been five publications in peer-reviewed journals addressing both clinical experience with ADASUVE and the pharmacoeconomics of using ADASUVE, highlighting the costs and burden of established habits of dealing with agitated patients."
ADASUVE saves time and money, helping overburdened medical systems. Patients suffer less. Hospital staff are safer.

Bonus label expansion potential:
"Ferrer recently met with the EU regulatory authorities to explore the potential modification of the ADASUVE label in Europe to allow the use of the product in the outpatient setting."

Sales are thus expected to shift higher. Costs are expected to move lower as production schedule can wind down. EPS can thus gain significantly over the next year. Possible new company strategy can be an additional catalyst for stock price appreciation.